Clinical experience with drug-eluting stents.
Despite dramatic improvements in catheter and stent technology, in-stent restenosis continues to hamper initial procedural success in 10% to 50% of patients undergoing coronary intervention. Recent breakthroughs in polymer science and local drug delivery have shown tremendous promise in the long-sought-after goal of delivering antirestenotic therapy directly from a stent. Clinical trials examining several novel antirestenotic agents, particularly sirolimus and paclitaxel, have shown astonishing reduction in restenosis following stenting. Through examination of the clinical experience to date, we may gain insight into the current and future utility of drug-eluting stents in our clinical practice.
Drachman
Douglas E
DE
Department of Medicine, (Knight Cardiac Catheterization Laboratory, Cardiovascular Division, Massachusetts General Hospital) Harvard Medical School, Boston, Massachusetts, USA.
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D023903:Coronary Restenosis / Q000517:prevention & control*; D016503:Drug Delivery Systems / Q000295:instrumentation*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D017239:Paclitaxel / Q000627:therapeutic use; D011108:Polymers / Q000737:chemistry; D020123:Sirolimus / Q000627:therapeutic use; D015607:Stents; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D007166:Immunosuppressive Agents; D011108:Polymers; D017239:Paclitaxel; D020123:Sirolimus